Elanco Animal Health (ELAN) Stock: Buy, Sell, or Hold?
ELAN - Elanco Animal Health Incorporated Common Stock
$23.17
0.31 (1.36%)
â˛
5d:
-5.12%
30d:
+4.7%
90d:
-3.66%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When ELAN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ELAN is fairly priced but lacks strong directional signals. At -4.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ELAN is fairly priced but lacks strong directional signals. At -4.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$39.94
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$24.80
6.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ELAN is currently trading at $23.17, which is considered slightly low relative to its 30-day fair value range of $22.92 to $24.99. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.1) compared to its historical average (20.8). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This pessimistic expectation contrasts with the company's recent 440.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ELAN is in a uptrend. The price is currently testing key support at $22.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ELAN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $31.21 (+34.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ELAN is in a uptrend. The price is currently testing key support at $22.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ELAN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $31.21 (+34.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$22.92 -
$24.99
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding ELAN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.7% below Wall St target ($31.21)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$22.92 -
$24.99
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$22.65
Resistance Level
$25.07
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.11
Wall Street Target
$31.21
(+34.7%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
440.5%
Profit Margin
-4.0%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
18.1 vs 20.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$22.15
(-4%)
2-Year Target
$21.18
(-9%)
3-Year Target
$20.24
(-13%)
3-Yr Target (if PE normalizes)
(PE: 18â21)
$23.26
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 13.0%)
$37.24
(+61%)
Base:
(SPY PE: 18.1, Growth: 13.0%)
$33.43
(+44%)
Bear:
(PE: 15.4, Growth: 13.0%)
$28.42
(+23%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.1 to 20.8
Stabilization Target:
$26.62
(+14.9%)
PE Expansion Potential:
+14.9%
Share & Embed Analysis
Last updated: September 13, 2026 11:37 AM ET
Data refreshes hourly during market hours. Next update: 12:37 PM
Data refreshes hourly during market hours. Next update: 12:37 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELAN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced ELAN Option Strategies
Professional options setups generated by AI based on today's ELAN price and gamma walls.
